{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:54:57Z","timestamp":1793253297971,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Limited clinical evidence is available about the risk of neurodevelopmental disorders (NDD), including autism spectrum disorders and congenital malformations (CM), in offspring following paternal exposure to antiseizure medications.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the risk of NDD (any subtype) and CM (major and\/or minor) in offspring paternally exposed to valproate vs lamotrigine or levetiracetam monotherapy within 3 months prior to conception.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This observational, population-based, nationwide cohort study used Nordic registries data with family linkage (offspring born between 1997-2018 [Denmark], 2010-2019 [Norway], and 2007-2019 [Sweden]). Offspring born within the study period and paternally exposed to either (1) valproate or (2) lamotrigine or levetiracetam were identified and followed-up until 12 years or the end of the study period, whichever came first. Data were obtained from October 2020 (Denmark), June 2021 (Norway), and March 2021 in Sweden)and analyzed from October 2020 to July 2023.<\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Paternal exposure to (1) valproate or (2) lamotrigine or levetiracetam during the spermatogenic risk window (derived from each National Prescription Registry).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary and secondary outcomes were NDD and CM, respectively, in offspring aged 12 years or younger. Country-specific hazard ratios (HRs) for NDD were estimated using Cox regression models and propensity score weighting (PSW), subsequently pooled via meta-analysis. Odds ratios (ORs) for CM were estimated using unadjusted logistic regression models for Denmark and Norway, but were not estimated for Sweden due to database constraints.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n NDD analysis included 5721 offspring, with 1950 in Denmark (valproate: 793 offspring; lamotrigine or levetiracetam: 1157 offspring), 1416 in Norway (valproate: 398 offspring; lamotrigine or levetiracetam: 1018 offspring), and 2355 in Sweden (valproate: 930 offspring; lamotrigine or levetiracetam: 1425 offspring). After excluding offspring with outlier weights and\/or incomplete observation in the PSW-adjusted analyses, NDD occurrence was observed in 38 of 678 offspring (5.6%) vs 36 of 1118 offspring (3.2%), 13 of 325 offspring (4.0%) vs 21 of 910 offspring (2.3%), and 47 of 841 offspring (5.6%) vs 34 of 1334 offspring (2.5%) exposed to valproate vs lamotrigine or levetiracetam in Denmark, Norway, and Sweden, respectively. PSW-adjusted analyses showed significantly higher risk in the valproate vs lamotrigine or levetiracetam group (pooled adjusted HR, 1.50; 95% CI: 1.09-2.07;\n P<\/jats:italic>\n \u2009=\u2009.01). CM analysis included 1161 offspring, with 648 in Denmark (valproate: 259 offspring; lamotrigine or levetiracetam: 389 offspring) and 513 in Norway (valproate: 169 offspring; lamotrigine or levetiracetam: 344 offspring), and found no increased risk (unadjusted pooled OR, 0.81; 95% CI, 0.48-1.36).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, higher NDD risk was observed in offspring paternally exposed to valproate vs lamotrigine or levetiracetam, but no difference in CM risk was observed between the 2 exposure groups. However, these findings should be interpreted with caution due to the heterogeneity in the unadjusted estimates.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.42581","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T16:30:55Z","timestamp":1762792255000},"page":"e2542581","source":"Crossref","is-referenced-by-count":19,"title":["Paternal Valproate Use and Neurodevelopmental Disorder and Congenital Malformation Risk in Offspring"],"prefix":"10.1001","volume":"8","author":[{"given":"Sandrine","family":"Colas","sequence":"first","affiliation":[{"name":"Patient Safety & Pharmacovigilance, Epidemiology & Benefit-Risk Evaluation, Sanofi, Gentilly, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Longin","sequence":"additional","affiliation":[{"name":"Contractor, Epidemiology & Benefit-Risk Evaluation, Sanofi, Gentilly, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Cristina","family":"Santos","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Department of Pharmacoepidemiology, Teva Pharmaceutical Industries, Netanya, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romina","family":"di Giuseppe","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bigat","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Sanofi, Gentilly, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Venerus","sequence":"additional","affiliation":[{"name":"EMEA Real World Methods & Evidence Generation, IQVIA Solutions Italy S.r.l, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte-Helene","family":"Bj\u00f8rk","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, University of Bergen, Bergen, Norway"},{"name":"Department of Neurology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Laure","family":"K\u00fcrzinger","sequence":"additional","affiliation":[{"name":"Patient Safety & Pharmacovigilance, Epidemiology & Benefit-Risk Evaluation, Sanofi, Gentilly, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Roberta","family":"Cilio","sequence":"additional","affiliation":[{"name":"Division of Pediatric Neurology, Institute of Neuroscience, Saint-Luc University Hospital, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Richy","sequence":"additional","affiliation":[{"name":"Real World Solutions, IQVIA, Brussels, Belgium"},{"name":"Now with:University of Liege, Liege, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"10","key":"zoi251160r3","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30144","article-title":"Measures to mitigate sodium valproate use in pregnant women with epilepsy.","volume":"14","author":"Ranjith","year":"2022","journal-title":"Cureus"},{"issue":"9","key":"zoi251160r4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1136\/jnnp-2013-306318","article-title":"Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers.","volume":"85","author":"Campbell","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"21","key":"zoi251160r5","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy.","volume":"78","author":"Hern\u00e1ndez-D\u00edaz","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"zoi251160r6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/epi.13632","article-title":"Malformation risk of antiepileptic drug exposure during pregnancy in women with epilepsy: results from a pregnancy registry in South India.","volume":"58","author":"Thomas","year":"2017","journal-title":"Epilepsia"},{"issue":"9","key":"zoi251160r7","doi-asserted-by":"publisher","first-page":"e831","DOI":"10.1212\/WNL.0000000000008001","article-title":"Declining malformation rates with changed antiepileptic drug prescribing: an observational study.","volume":"93","author":"Tomson","year":"2019","journal-title":"Neurology"},{"issue":"7","key":"zoi251160r8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-017248","article-title":"Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis.","volume":"7","author":"Veroniki","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"zoi251160r9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","article-title":"Teratogenicity of antiepileptic drugs.","volume":"32","author":"Tomson","year":"2019","journal-title":"Curr Opin Neurol"},{"issue":"7","key":"zoi251160r10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamaneurol.2022.1269","article-title":"Association of Prenatal exposure to antiseizure medication with risk of autism and intellectual disability.","volume":"79","author":"Bj\u00f8rk","year":"2022","journal-title":"JAMA Neurol"},{"issue":"16","key":"zoi251160r11","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.2013.2270","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism.","volume":"309","author":"Christensen","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"zoi251160r12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2309359","article-title":"Risk of autism after prenatal topiramate, valproate, or lamotrigine exposure.","volume":"390","author":"Hern\u00e1ndez-D\u00edaz","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi251160r13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.yebeh.2007.08.022","article-title":"Postnatal concerns in children born to women with epilepsy.","volume":"11","author":"Holmes","year":"2007","journal-title":"Epilepsy Behav"},{"issue":"3","key":"zoi251160r14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S1474-4422(12)70323-X","article-title":"Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study.","volume":"12","author":"Meador","year":"2013","journal-title":"Lancet Neurol"},{"issue":"12","key":"zoi251160r15","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1111\/epi.17085","article-title":"Prenatal exposure to valproate and risk of congenital malformations\u2014could we have known earlier? A population-based cohort study.","volume":"62","author":"Christensen","year":"2021","journal-title":"Epilepsia"},{"issue":"8","key":"zoi251160r16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010224.pub3","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child.","volume":"8","author":"Bromley","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"zoi251160r17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamaneurol.2024.0258","article-title":"Risk of major congenital malformations and exposure to antiseizure medication monotherapy.","volume":"81","author":"Battino","year":"2024","journal-title":"JAMA Neurol"},{"issue":"4","key":"zoi251160r19","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/j.1365-2125.2012.04426.x","article-title":"Effects of preconceptional paternal drug exposure on birth outcomes: cohort study of 340?000 pregnancies using Norwegian population-based databases.","volume":"75","author":"Engeland","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"zoi251160r20","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1136\/jnnp-2020-323028","article-title":"Paternal exposure to antiepileptic drugs and offspring outcomes: a nationwide population-based cohort study in Sweden.","volume":"91","author":"Tomson","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"zoi251160r21","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1111\/epi.12226","article-title":"Exposure to antiepileptic drugs in utero and child development: a prospective population-based study.","volume":"54","author":"Veiby","year":"2013","journal-title":"Epilepsia"},{"issue":"7","key":"zoi251160r22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s10654-019-00509-2","article-title":"Preconceptional paternal antiepileptic drugs use and risk of congenital anomalies in offspring: a nationwide cohort study.","volume":"34","author":"Yang","year":"2019","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"zoi251160r23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.14709","article-title":"Valproate use during spermatogenesis and risk to offspring.","volume":"7","author":"Christensen","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi251160r24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/(SICI)1096-9926(199909)60:3<161::AID-TERA12>3.0.CO;2-A","article-title":"Teratogen update: paternal exposures-reproductive risks.","volume":"60","author":"Trasler","year":"1999","journal-title":"Teratology"},{"key":"zoi251160r25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ntt.2019.106837","article-title":"Paternal valproic acid exposure in mice triggers behavioral alterations in offspring.","volume":"76","author":"Ibi","year":"2019","journal-title":"Neurotoxicol Teratol"},{"key":"zoi251160r28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/CLEP.S314959","article-title":"Nordic Health Registry\u2013based research: a review of health care systems and key registries.","volume":"13","author":"Laugesen","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"7","key":"zoi251160r29","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System.","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"issue":"10","key":"zoi251160r30","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3390\/genes13101821","article-title":"Autism with epilepsy: a neuropsychopharmacology update.","volume":"13","author":"Canitano","year":"2022","journal-title":"Genes (Basel)"},{"issue":"4","key":"zoi251160r31","article-title":"Adverse pregnancy outcomes associated with gestational exposure to antiepileptic drugs.","volume":"79","author":"Andrade","year":"2018","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"zoi251160r32","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-034829","article-title":"Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study.","volume":"10","author":"Bloti\u00e8re","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"zoi251160r33","doi-asserted-by":"crossref","first-page":"17362","DOI":"10.1038\/s41598-020-74409-x","article-title":"Risk of early neurodevelopmental disorders associated with in utero exposure to valproate and other antiepileptic drugs: a nationwide cohort study in France.","volume":"10","author":"Coste","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"zoi251160r34","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/ane.12965","article-title":"Antiepileptic drug polytherapy in pregnant women with epilepsy.","volume":"138","author":"Vajda","year":"2018","journal-title":"Acta Neurol Scand"},{"issue":"12","key":"zoi251160r37","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1136\/jnnp-2018-318386","article-title":"In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring.","volume":"89","author":"Bech","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"zoi251160r38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1186\/s12879-018-3423-z","article-title":"Oseltamivir in pregnancy and birth outcomes.","volume":"18","author":"Ehrenstein","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"23","key":"zoi251160r39","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","article-title":"Valproic acid monotherapy in pregnancy and major congenital malformations.","volume":"362","author":"Jentink","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi251160r40","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1023\/A:1010933404324","article-title":"Random forests.","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach Learn"},{"issue":"5","key":"zoi251160r41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.12139","article-title":"Risk of Neurodevelopmental Disorders and Paternal Use of Valproate During Spermatogenesis.","volume":"8","author":"Christensen","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"zoi251160r42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/jnnp-2024-334077","article-title":"Paternal exposure to antiseizure medications and offspring outcomes: a systematic review.","volume":"96","author":"Honybun","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"zoi251160r43","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1071181","article-title":"The global prevalence of autism spectrum disorder: a three-level meta-analysis.","volume":"14","author":"Talantseva","year":"2023","journal-title":"Front Psychiatry"},{"key":"zoi251160r44","doi-asserted-by":"crossref","DOI":"10.1007\/s10803-025-06997-4","article-title":"The effect of different algorithms on prevalence of attention deficit hyperactivity disorder and autism spectrum disorder in secondary healthcare data in five European countries: a contribution from the ConcePTION project.","author":"Given","year":"2025","journal-title":"J Autism Dev Disord"},{"key":"zoi251160r45","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2147\/NDT.S466081","article-title":"Prevalence of autism in Scandinavian Countries (Denmark, Norway, Sweden), and Nordic countries (Finland, Iceland, the Faroe Islands, and Greenland).","volume":"20","author":"Jensen de L\u00f3pez","year":"2024","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"zoi251160r46","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12884-023-06242-9","article-title":"Neurodevelopmental outcomes after prenatal exposure to lamotrigine monotherapy in women with epilepsy: a systematic review and meta-analysis.","volume":"24","author":"Peron","year":"2024","journal-title":"BMC Pregnancy Childbirth"},{"issue":"1","key":"zoi251160r47","doi-asserted-by":"crossref","first-page":"9640","DOI":"10.1038\/s41467-024-53813-1","article-title":"Antiseizure medication use during pregnancy and children\u2019s neurodevelopmental outcomes.","volume":"15","author":"Madley-Dowd","year":"2024","journal-title":"Nat Commun"},{"key":"zoi251160r48","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.7861\/clinmedicine.18-2-s1","article-title":"Valproate: life-saving, life-changing.","volume":"18","author":"Thomas","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"zoi251160r49","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109941","article-title":"Quality of life in children with epilepsy: the role of parental mental health and sleep disruption.","volume":"158","author":"Winsor","year":"2024","journal-title":"Epilepsy Behav"},{"key":"zoi251160r2","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"zoi251160r1","unstructured":"European Medicines Agency. Valproate and related substances\u2014referral. EMA. Updated June 7, 2018. Accessed June, 19 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/valproate-related-substances-0"},{"key":"zoi251160r18","unstructured":"European Medicines Agency. PRAC recommends new measures to avoid valproate exposure in pregnancy. Published February 9, 2018. Accessed June 19, 2024. https:\/\/www.ema.europa.eu\/en\/news\/prac-recommends-new-measures-avoid-valproate-exposure-pregnancy#PPP."},{"key":"zoi251160r26","unstructured":"Norweigan Tax Administration. Paternity. Accessed October 20, 2025. https:\/\/www.skatteetaten.no\/en\/person\/national-registry\/birth-and-name-selection\/paternity-and-parental-responsibility\/?"},{"key":"zoi251160r27","unstructured":"Swedish Birth Registry. New parents. Skatteverket. Accessed October 10, 2025. https:\/\/www.skatteverket.se\/servicelankar\/otherlanguages\/englishengelska\/individualsandemployees\/livinginsweden\/newparents.4.7be5268414bea064694c754.html"},{"key":"zoi251160r35","unstructured":"European Surveillance of Congenital Anomalies. EUROCAT Guide 1.4: Instruction for registration of congenital anomalies. Updated November 22, 2021. Accessed October 10, 2025. https:\/\/eu-rd-platform.jrc.ec.europa.eu\/system\/files\/public\/JRC-EUROCAT-Full%20Guide%201%204%20version%2022-Nov-2021.pdf"},{"key":"zoi251160r36","unstructured":"European Medicines Agency. Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines: PRAC recommends precautionary measures. Published January 12, 2014. Accessed October 10, 2025. https:\/\/www.ema.europa.eu\/en\/news\/potential-risk-neurodevelopmental-disorders-children-born-men-treated-valproate-medicines-prac-recommends-precautionary-measures."}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2841180\/colas_2025_oi_251160_1762199937.54295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T16:30:58Z","timestamp":1762792258000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2841180"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.42581","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}